Ricerc@Sapienza

Metabolic reprogramming provides critical information for clinical oncology. Using molecular
data of 9,125 patient samples from The Cancer Genome Atlas, we identified tumor subtypes in 33
cancer types based on mRNA expression patterns of seven major metabolic processes and assessed
their clinical relevance. Our metabolic expression subtypes correlated extensively with clinical
outcome: subtypes with upregulated carbohydrate, nucleotide, and vitamin/cofactor metabolism

Introduction: The risk-benefit profile of any pharmacologic agent must be evaluated against risks connected with the events to be avoided. This is especially true in the case of hormonal contraception, not intended to combat a disease. Over the six decades during which their use has progressively expanded, the risk-benefit profile of combined oral contraceptives (COC) has substantially changed, with new combinations, dosages and mode of administration appearing on the market.